Corbus Pharmaceuticals Holdings, Inc.
CRBP
$7.70
$0.141.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 74.27M | 70.10M | 60.48M | 50.42M | 42.10M |
| Gross Profit | -74.27M | -70.10M | -60.48M | -50.42M | -42.10M |
| SG&A Expenses | 15.57M | 15.22M | 15.47M | 16.61M | 16.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.84M | 85.31M | 75.95M | 67.04M | 58.87M |
| Operating Income | -89.84M | -85.31M | -75.95M | -67.04M | -58.87M |
| Income Before Tax | -84.53M | -78.54M | -67.51M | -57.95M | -50.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.53 | -78.54 | -67.51 | -57.95 | -50.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.53M | -78.54M | -67.51M | -57.95M | -50.29M |
| EBIT | -89.84M | -85.31M | -75.95M | -67.04M | -58.87M |
| EBITDA | -89.64M | -85.08M | -75.63M | -66.62M | -58.36M |
| EPS Basic | -5.81 | -5.98 | -5.51 | -4.76 | -4.23 |
| Normalized Basic EPS | -3.68 | -3.78 | -3.65 | -3.18 | -2.85 |
| EPS Diluted | -5.81 | -5.98 | -5.51 | -4.76 | -4.23 |
| Normalized Diluted EPS | -3.68 | -3.78 | -3.65 | -3.18 | -2.85 |
| Average Basic Shares Outstanding | 59.74M | 53.23M | 48.93M | 48.64M | 47.45M |
| Average Diluted Shares Outstanding | 59.74M | 53.23M | 48.93M | 48.64M | 47.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |